Characteristics of Participants with Mild to Moderate MGD Utilizing AZR-MD-001 0.5% in a Randomized, Placebo-Controlled, Phase 3 Trial

AZR-MD-001 - Azura Ophthalmics

Kelly Nichols1; Francis Mah2; David Wirta3; Preeya Gupta4; Yair Alster5; Charles Bosworth5

Mar 26, 2025